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A B S T R A C T   
Neurological diseases constitute a quarter of global disease burden and are expected to rise worldwide with the 
ageing of human populations. There is an increasing need to develop new molecular systems which can deliver 
drugs speciically into neurons, non-dividing cells meant to last a human lifetime. Neuronal drug delivery must 
rely on agents which can recognise neurons with high speciicity and afinity. Here we used a recently introduced 
‘stapling’ system to prepare macromolecules carrying duplicated binding domains from the clostridial family of 
neurotoxins. We engineered individual parts of clostridial neurotoxins separately and combined them using a 
strong alpha-helical bundle. We show that combining two identical binding domains of tetanus and botulinum 
type D neurotoxins, in a sterically deined way by protein stapling, allows enhanced intracellular delivery of 
molecules into neurons. We also engineered a botulinum neurotoxin type C variant with a duplicated binding 
domain which increased enzymatic delivery compared to the native type C toxin. We conclude that duplication 
of the binding parts of tetanus or botulinum neurotoxins will allow production of high avidity agents which could 
deliver imaging reagents and large therapeutic enzymes into neurons with superior eficiency.   
1. Introduction 
The intractable nature of many neurological disorders demands new 
approaches to deliver medications into neurons with high precision. 
Neurons are highly specialised cells carrying a unique set of lipids, 
carbohydrates and proteins, which together help to achieve the primary 
goal of neurons – fast transmission of information. The neuronal mem-
brane is rich in complex gangliosides such as GD1a and GT1b which play 
an essential role in myelination of long, fast conducting axons (Vyas and 
Schnaar, 2001). Neurons are also rich in fast-conducting ion channels 
and proteins governing synaptic vesicle formation, loading of vesicles 
with neurotransmitters and stimulus-driven release of neurotransmitters 
from nerve endings. In the case of the neuromuscular junction, the 
release of acetylcholine results in immediate muscle contraction, 
whereas in CNS the release of glutamate, for example, leads to fast 
propagation of information. Prior to neurotransmitter release, synaptic 
vesicles fuse with the plasma membrane and a set of three proteins plays 
the critical role in this process of fusion (Sollner et al., 1993). The three 
proteins are syntaxin and SNAP-25 on the plasma membrane, and 
vesicle-associated membrane protein (VAMP), also known as synapto-
brevin (Sollner et al., 1993). These three proteins, Soluble N-ethyl-
maleimide-sensitive factor Attachment Protein REceptors (SNAREs), 
form a tight helical bundle which bridges vesicular and plasma mem-
branes, causing the two lipid bilayers to merge with subsequent release 
of neurotransmitters (Sutton et al., 1998). Identiication of the SNARE 
proteins in the early 1990s led to a breakthrough in our understanding of 
the actions of the most potent toxins known to man – clostridial neu-
rotoxins, tetanus toxin and botulinum neurotoxins (BoNTs), all of which 
cause long-lasting and yet reversible paralysis (Rossetto et al., 2014; 
Hayashi et al., 1994). The family of neuron-speciic BoNTs consist of 
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seven classical serotypes (A-G), each cleaving a speciic SNARE protein 
to cause a long-lasting laccid paralysis, which may result in death 
(Rossetto et al., 2014; Hayashi et al., 1994). BoNTs type A, C and E 
cleave SNAP-25, while BoNTs type B, D, F and G cleave VAMPs, 
vesicle-associated membrane proteins (Binz, 2013). Unlike BoNTs, 
tetanus toxin cleaves neuronal VAMP proteins in the spinal cord after 
hijacking the retrograde transport operating inside motor neurons and 
this cleavage of VAMPs lead to spastic paralysis (Surana et al., 2018). 
Clostridial neurotoxins target only neurons without any apparent 
cross-binding to other cells. These neurotoxins are precisely engineered 
proteins composed of three domains with their speciic autonomous 
functions (Montal, 2010). Both tetanus toxin and BoNTs are 150-kDa 
proteins consisting of a 50-kDa enzymatic SNARE-cleaving light chain 
(LC) linked by a disulphide bond to a 100-kDa heavy chain, which 
contains two major structural domains – binding and translocation do-
mains (Montal, 2010). The binding domain, namely C-terminal half of 
the heavy chain (Hc), binds to neuronal receptors – gangliosides GT1b 
and GD1a, and synaptic vesicle proteins, the latter becoming exposed on 
neurons after release of transmitters and before recovery by endocytosis 
(Surana et al., 2018; Montal, 2010). Once in the endocytic vesicle, the 
N-terminal half of the heavy chain (Hn) forms a channel in the endo-
some membrane through which the LC escapes into the presynaptic 
cytosol, while the reducing cytosolic environment severs the disulphide 
bond (Montal, 2010). In the case of BoNT/A, LC diffuses throughout the 
neuronal cytosol and cleaves the plasma membrane-associated SNAP-25 
resulting in nerve block (Schiavo et al., 1993; Binz et al., 1994). For 
simplicity, the botulinum neurotoxin structure can be described as 
LCHn/Hc where Hc represents the binding module. 
Among the seven BoNTs, type A (BoNT/A) has proved successful in 
alleviating symptoms of over 100 medical conditions arising from nerve 
over-activity, e.g., dystonias, spasticity, chronic migraine and auto-
nomic hypersecretory disorders (Jankovic, 2004). As mentioned above, 
BoNT-induced nerve blockade is a direct consequence of cleavage of 
SNARE proteins: in the case of BoNT/A, it deletes just 9 amino acids 
from the C terminus of SNAP-25 preventing the merger of vesicular and 
plasma membranes (Schiavo et al., 1993; Binz et al., 1994). The removal 
of 9 amino acids does not prevent the SNARE bundle formation thereby 
trapping vesicles in a docked state until the neuron regenerates the 
whole nerve terminal, involving membrane remodelling (Ovsepian 
et al., 2019). The lasting persistence of cleaved SNAP-25 in 
BoNT/A-intoxicated neurons allowed a design of a unique antibody 
which recognises the BoNT/A-generated cleaved end of SNAP-25 
(Yadirgi et al., 2017). This neoepitope antibody proved to be useful to 
observe the location of BoNT/A action both in vitro and in vivo and we 
exploited this antibody to study the effects of delivering botulinum 
enzyme using duplicated clostridial binding domains. 
Duplication of binding domains is often observed in nature where 
high avidity is required for protein function (Vauquelin and Charlton, 
2013). Examples of multiplication of binding domains occurring in 
natural molecules include antibodies, lectins and protein toxins (Vau-
quelin and Charlton, 2013; Roy et al., 2016; Davletov et al., 2012). We 
now show the functional effects of artiicially duplicating the binding 
domains of tetanus and botulinum type C and D domains as prototype 
vehicles for delivery of drugs into the CNS. Our results show that a mere 
duplication of the Hc domains causes highly signiicant escalation of 
neuronal delivery of small molecules and enzymatic activity. We also 
observed an increase in the speed of action of novel botulinum con-
structs, which could be exploited for potential therapeutic beneits. 
2. Results 
2.1. Duplication of the tetanus binding domain 
Our molecular stapling system utilises a truncated SNARE bundle 
and allows on-demand combination of protein parts upon simple mixing 
(Darios et al., 2010). For protein linking we used three shortened SNARE 
helical polypeptides which we call here linkers 1, 2 and 3 (green, yellow 
and blue). These three linkers assemble spontaneously within 1 h into a 
highly stable helical bundle permitting on-demand conjugation of pro-
teins (Fig. 1). 
The binding domain of tetanus neurotoxin (HcT) has been used by 
many groups for delivery of imaging reagents and therapeutics due to its 
well-known ability to bind motor neurons (Surana et al., 2018; Toivonen 
et al., 2010). We genetically fused HcT either to linkers 1 or 2 while 
linker 3 was prepared separately for chemical attachment of a luores-
cent cargo. The linkers with or without HcT proteins were expressed in 
E. coli and puriied by afinity chromatography and gel-iltration on a 
Superdex-200 column. Maleimide-Cy3 was used to chemically label the 
linker 3 via cysteine groups. We then prepared 2xHcT and 1xHcT car-
rying the Cy3 luorescent label, named 2xHcT-Cy3 and 1xHcT-Cy3 
(Fig. 1a, upper panel, and Fig. 1b). The two molecules were applied to 
rat cortical neurons and bound luorescence was imaged and quantiied. 
Fig. 1c shows that 2xHcT-Cy3 exhibited 2.6-fold more internalisation 
into primary neurons compared to 1xTet-Cy3. We next investigated 
whether duplication of the tetanus binding domain can enhance 
neuronal delivery of the botulinum type A protease (LCHn/A). We chose 
LCHn/A as a cargo because its activity can be conveniently detected by 
SNAP-25 cleavage with highest possible sensitivity, whereas the cleav-
age of VAMP protein is more dificult to detect in situ (Yadirgi et al., 
2017; Gray et al., 2018). After expression in bacteria, LCHn/A fused to 
linker 3 was puriied by afinity chromatography and gel-iltration. 
Mixing the two HcTs in the presence of LCHn/A-linker3 led to forma-
tion of 225 kDa SDS-resistant chimeric protein which we call Bitox/TT 
(Fig. 1d). Formation of ‘single binding’ Bitox/T was achieved by mixing 
HcT-linker 1 with LCHn/A-linker 3 in the presence of linker 2 alone, 
yielding a 175 kDa construct (Fig. 1d). We compared the eficiency of 
the cleavage of intra-neuronal SNAP-25 by Bitox/TT versus Bitox/T in 
rat cortical neuronal cultures. Fig. 1e and f shows that Bitox/TT caused 
28 fold enhancement of neuronal SNAP-25 cleavage indicating that the 
duplication of binding domain can lead to enhancement of enzymatic 
delivery into neurons. 
Next, we investigated the properties of double-binding tetanus 
molecules in motor neurons, the natural target of tetanus toxin. 2xHcT- 
Cy3 and 1xHcT-Cy3 were applied to mouse motor neurons and bound 
luorescence was imaged and quantiied. Fig. 2a shows that 2xHcT-Cy3 
exhibited 2.5-fold more binding to motor neurons compared to 1xTet- 
Cy3, similar to the results obtained in cortical neuronal cultures. Can 
duplication of HcT cause an enhanced delivery in vivo? To answer this 
question, 2xHcT-Cy3 (1 μg, 8 pmol) and 1xHcT-Cy3 (1 μg, 13 pmol) 
were injected into mouse hind paws and after three days spinal cords 
were sectioned and analysed by luorescent microscopy. Fig. 2b shows a 
50% increase in accumulation of Cy3 signal for the duplicated molecule 
in the cell bodies of motor neurons in the ipsilateral ventral horn of 
injected animals despite the lower amount of 2xHcT in the injection. To 
evaluate if such an increase is due to acceleration of axonal transport, we 
analysed intraneuronal traficking in cultured motor neurons (Terenzio 
et al., 2014). We applied 10 nM 1xHcT-Cy3 and 2xHcT-Cy3 to the 
chamber containing terminals of primary motor neurons for 30 min and 
after washing, the axonal retrograde transport of the luorescent mole-
cules was imaged and quantiied in microluidic devices. The frequency 
and brightness of the retrograde transport carriers were very similar 
between the two HcT constructs suggesting that the sorting pathway to 
these organelles is similar under these conditions (Fig. 2c). It was 
evident that the dual HcT follows the canonical internalisation pathway 
and both constructs moved along the microtubules with the same speed 
(Fig. 2c), suggesting that binding to the neuronal membrane is the 
critical step. We next investigated whether enhanced uptake of Bitox/TT 
could result in augmentation of exogenous enzymatic activity in the 
spinal cord of rats. We measured the botulinum enzymatic activity by 
quantifying the proteolytic cleavage of SNAP-25 using the neoepitope 
antibody against the cleaved SNAP-25 (Yadirgi et al., 2017). As observed 
previously for Bitox/T (Ferrari et al., 2013), injections of Bitox/TT did 
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not induce any noticeable behavioural change with rats moving freely. 
Analysis of the spinal cord using immunohistochemistry with the 
neoepitope-SNAP-25 antibody revealed a signiicant cleavage of 
SNAP-25 in the ventral horn area surrounding motor neurons in the case 
of Bitox/T (Fig. 2d). This cleavage was dramatically enhanced in the 
case of Bitox/TT with almost the whole ipsilateral side of the spinal cord 
at L4-5 level exhibiting the SNAP-25 cleavage (Fig. 2d-f). Quantiication 
of the percentage of SNAP25-cleaved area relevant to the total section 
area showed a four-fold increase in the area of penetration of botulinum 
activity in the case of Bitox/TT: BiTox/T ¼ 15.6 � 3, BiTox/TT ¼ 44.7 �
5. Further we investigated retrograde transport after a local injection 
into the visual cortex of mice. We injected the toxins in the binocular 
portion of the visual cortex, to maximise callosal neuron uptake (and 
thus long-range traficking) (Restani et al., 2009). Three days following 
injection, we dissected tissues corresponding to injected and contralat-
eral visual cortices (Fig. 2g). Western blots were performed and quan-
tiied for the levels of cleaved SNAP-25. Ipsilaterally, at the site of 
injection, the cleavage of SNAP-25 was strong in both cases (data not 
shown). However, immunoblotting analysis of the contralateral visual 
cortex revealed that Bitox/TT caused a four-fold stronger enzymatic 
action in the contralateral side compared to Bitox/T (Fig. 2g). 
We therefore conclude that duplication of tetanus binding domain 
can eficiently increase delivery of both small molecules and enzymes 
into neurons both in vitro and in vivo. 
2.2. Duplication of type D botulinum binding domain 
We next focused on the botulinum protein-based neuronal delivery 
because humans are not routinely immunised against botulinum neu-
rotoxins in contrast to the global tetanus vaccination programme. 
Therefore botulinum-based delivery vehicles are more likely to be used 
in future medicine. BoNTs type A and type B are well known thera-
peutics already used to cause temporary muscle paralysis or reduce 
excessive secretory functions (Ovsepian et al., 2019). To avoid potential 
immune cross-reaction with type A and type B botulinum drugs, we 
decided to focus on other types of botulinum binding domains. We chose 
Fig. 1. Duplication of tetanus binding domain results in increased binding to neurons and augmented cleavage of SNAP-25 in neurons. a) Schematic showing 
structural features of tetanus and botulinum neurotoxins together with chimeric proteins used. The coloured bridge is formed by three linking polypeptides. Red star 
indicates Cy3 luorophore chemically attached to one of the linking peptides. b) SDS-PAGE gel showing 1xHcT-Cy3 and 2xHcT-Cy3 after the 60 min assembly 
reaction. Proteins were visualised by Coomassie staining (upper panel) and luorescence (lower panel). c) Examples of luorescent micrographs (left) and their 
quantiication (right) of cultured rat cortical neurons treated with either 1xHcT-Cy3 or 2xHcT-Cy3 (both 10 nM, red). Nuclear staining was done using Hoechst 3342 
stain (blue). Bar chart shows mean Cy3 intensity (red, n ¼ 3). d) Coomassie-stained SDS-PAGE gel showing formation of Bitox/T and Bitox/TT and the difference in 
their apparent molecular weights. Proteins were analysed in non-reducing conditions and thus exhibit full protein content. e) Duplication of tetanus binding domain 
increases SNAP-25 cleaving activity of tetanus-botulinum type A stapled chimera. Example immunoblot of rat cortical neurons treated with either Bitox/T or Bitox/ 
TT at the indicated concentrations (n ¼ 3). f) Immunoanalysis reveals signiicant enhancement of the cleavage of SNAP-25 (S25) for Bitox/TT: BiTox/T ¼ 120 pM, 
BiTox/TT ¼ 4.4 pM (n ¼ 3). 
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type D botulinum binding domain in order to devise an enhanced 
neuronal delivery system as our previous study demonstrated the po-
tential of BoNT/D as a neuronal delivery vehicle (Bade et al., 2004). We 
expressed Hc type D, HcD, fused to linkers 1 and 2 similar to the tetanus 
HcT domain. For evaluation of neuronal delivery of enzymatic activity, 
we exploited LCHn/A fused to linker 3. Upon assembly, the SDS-PAGE 
gel reveals a BiTox/DD having molecular weight of ~225 kDa 
compared to 175 kDa BiTox/D which can be accounted by the presence 
of an additional HcD in the former (Fig. 3a). The activity of BiTox/DD 
was evaluated in rat cortical neuronal cultures and differentiated human 
SiMa neuroblastoma cells which were shown previously to bind BoNTs 
type A to C. Direct comparison of SNAP-25 cleavage by BiTox/D and 
BiTox/DD revealed a strong enhancement of SNAP-25 cleavage in both 
human and rat neurons (one hundred fold) (Fig. 3b). 
2.3. BoNT/C with enhanced binding funding 
The enhanced neuronal action upon duplication of tetanus and bot-
ulinum D binding domains raises the question on whether it is possible 
to improve native full botulinum neurotoxins for medical use. Among 
the botulinum family of neurotoxins, BoNT/C and BoNT/D do not cause 
botulism in humans by ingestion (Rossetto et al., 2014) thus offering a 
degree of safety when engineering novel botulinum conigurations for 
exploring neuronal delivery of macromolecules. We attached a second 
HcC linked via a forty amino acid-lexible linker to the native BoNT/C 
yielding a single recombinant fusion protein (Fig. 4a). As an additional 
security step, we introduced a thrombin-activation site into the BoNT/C 
structure, just after the light chain, such that the molecule is fully active 
only after addition of thrombin as previously reported (Darios et al., 
2010). Fig. 4a shows the migration behaviour in an SDS-PAGE gel of the 
native BoNT/C and BoNT/CC, the latter carrying duplicated HcC and 
hence exhibiting a larger molecular weight. Direct comparison of the 
eficiency of SNAP-25 cleavage in SiMa neuroblastoma cells by the 
native BoNT/C and engineered BoNT/CC revealed a signiicant 
enhancement of SNAP-25 cleavage in the latter case, estimated to be 5 
fold (Fig. 4b). We and others reported that BoNT/C causes apoptosis of 
cultured neurons most likely due to elimination of plasma membrane 
SNAREs, which likely affects vesicle trafic required for nutrient uptake 
(Rust et al., 2016). To investigate a functional consequence of duplica-
tion of HcC we analysed neuronal survival in the presence of BoNT/C 
and BoNT/CC. After 65 h incubation, the Deep Blue cell viability assay 
reagent was added to the neuroblastoma cell media, and the luorescent 
signal was acquired at required wavelengths, Ex 560 nm/Em 590 nM. 
Fig. 4c shows that BoNT/CC caused a three-fold increase in cell death 
compared to native BoNT/C (BoNT/CC – 53.2%; BoNT/C – 13.8%). This 
result provides additional evidence that duplication of botulinum 
binding domains affords enhancement of botulinum activities within 
neurons. Finally, we investigated whether the kinetics of cleavage of 
SNAP-25 in SiMa neuronal cultures is accelerated upon duplication of 
HcC. Fig. 4d shows BoNT/CC caused cleavage of the majority of intra-
cellular SNAP-25 after 24 h whereas native BoNT/C at similar concen-
tration of 3 nM cleaved only half of SNAP-25. Quantiication of SNAP-25 
cleavage in three separate experiments revealed that duplication of the 
binding domain led to a two-fold acceleration of SNAP-25 cleavage in 
SiMa neuronal cultures. 
3. Discussion 
Novel ways to deliver imaging reagents and therapeutics to neurons 
will provide new opportunities to study the neuronal function in health 
and disease and will also allow better treatment of neurological diseases. 
More effective and better-tolerated pharmacological therapies for 
neurological disorders are urgently needed in the era of rapidly ageing 
population. Neurons are unique in that they are non-dividing cells with 
limited ability to renew their functions in disease or during the ageing 
process. Current treatments for neurological disorders often rely on 
systemic administration, resulting in multiple adverse effects due to off- 
target drug distribution, as exempliied by opioid pain-killers (Stein, 
2018). Another major obstacle in neurological treatment is the blood 
brain barrier (BBB), which prevents large molecules from entering the 
Fig. 2. Duplication of tetanus binding domain enhances neuronal delivery of Cy3 and botulinum enzyme in rodents. a) Examples of luorescent micrographs (left) 
and their quantiication (right) of cultured mouse motor neurons treated with either 1xHcT-Cy3 or 2xHcT-Cy3 (10 nM, scale bars, 25 μm). Bar chart shows average 
intensity normalised to tubulin/TUJ1 signal: 1xHcT-Cy3 ¼ 1 � 0.1, 2xHcT-Cy3 ¼ 2.5 � 0.5 (n ¼ 5). b) Schematic showing the injection site in mouse hind paw and 
the spinal cord area where SNAP-25 cleavage was quantiied (left panel). Spinal cord micrographs of mice injected intraplantar with either 1xHcT-Cy3 and 2xHcT- 
Cy3 indicating an increased accumulation of Cy3 label (red) in the ventral horn of the spinal cord in the latter case (middle panel). Bar chart showing 50% increase in 
the number of luorescent motor neurons in the most luorescent section of the spinal cord in the case of 2xHcT-Cy3 (right panel): 1xHcT ¼ 7.67 � 0.9; 2xHcT ¼ 11 �
0.6. c) Axonal retrograde traficking of HcT-containing carriers is not affected by duplication of tetanus binding domain. Quantiication of retrograde axonal 
transport was performed in cultured mouse motor neurons pulse-labelled with either 1xHcT-Cy3 or 2xHcT-Cy3 (both 10 nM) in microluidic devices. Cy3-positive 
carriers were tracked and their frequency and average speed were plotted in the graph (23 signalling endosomes, 217 transport steps). d-f) Example micrographs of 
whole spinal cords (d) and (e) or dorsal horn region (f) from rats injected intraplantar with either Bitox/T or Bitox/TT. Tissues were immunostained with cleaved 
SNAP-25 antibody (green) (d-f) and the NeuN neuronal marker (red) (d) and (f) (n ¼ 3). g) Schematic showing the injection site in the mouse visual cortex and the 
contralateral site where SNAP-25 cleavage was quantiied (left panel). An immunoblot of contralateral visual cortex of mice injected with Bitox/T or Bitox/TT. Note 
increased immunosignal of cleaved SNAP-25 (green) in the case of Bitox/TT compared to Bitox/T (middle panel). Bar chart showing four-fold increase in the 
quantiied immunosignals of cleaved SNAP-25 in the contralateral visual cortex of mouse brain (right panel) (n ¼ 8). 
Fig. 3. Duplication of botulinum type D binding domain results in augmented 
delivery of botulinum enzyme into neurons. a) Coomassie-stained SDS-PAGE 
gel showing formation of Bitox/D and Bitox/DD and the difference in their 
apparent molecular weights. Proteins were analysed in non-reducing conditions 
and thus exhibit full protein content. b) Duplication of HcD within novel bot-
ulinum type A stapled chimera increases cleavage of SNAP-25 in both rat 
cortical neurons (upper panel; BiTox/D EC50 ¼ 637 pM, BiTox/DD EC50 ¼ 6.4 
pM) and human neuroblastoma cells (n ¼ 3). 
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CNS from the vascular system (Ovsepian et al., 2016). Because of the 
BBB, achieving physiologically relevant doses of drugs in neural tissue 
by systemic delivery may require high, sometimes toxic, doses. To 
overcome these dificulties new delivery methods which circumvent the 
BBB and deliver drugs via peripheral neural pathways are under 
investigation. 
Here we explored, for the irst time, the effects of duplication of 
neural-binding domains derived from the clostridial neurotoxins on 
neurons in vitro and in vivo. Tetanus and botulinum neurotoxins are 
known to be the most potent agents to bind neurons causing spastic and 
laccid paralysis, respectively, at nanogram doses (Surana et al., 2018). 
They act by cleaving the SNARE proteins, thereby causing months-long 
nerve block (Rossetto et al., 2014). Without their SNARE-proteolytic 
action, these neurotoxins can be converted into powerful neural de-
livery vehicles. This can be achieved by inactivating the proteolytic 
clostridial enzymes via point-mutations as was demonstrated recently 
for BoNT/A and BoNT/C (Vazquez-Cintron et al., 2014, 2017). Impor-
tantly, in the case of the inactivated full-length neurotoxin the presence 
of the translocation domain permits drug delivery, via vesicular escape 
route, into the neuronal cytosol (Bade et al., 2004; Vazquez-Cintron 
et al., 2017). Alternatively, the structurally-independent neuronal 
binding domains of clostridial neurotoxins (Hc domain alone) can be 
produced separately and utilised for therapeutic or imaging cargo de-
livery into neurons (Surana et al., 2018). In the latter case, the Hc 
domain with the attached cargo would be retained in the endolysomal 
compartments and drugs/imaging agents will be released into the 
cytosol after proteolytic degradation. 
The tetanus neuronal binding domain has been utilised by many 
group to demonstrate successful delivery of imaging agents and thera-
peutics into the CNS after peripheral injection (Toivonen et al., 2010; 
Bergen et al., 2008). One problem for translation of tetanus-based drug 
delivery approach lies in the fact that humans are immunised against 
tetanus (Yen and Thwaites, 2019). This necessitates the use of smallest 
amounts possible to avoid triggering an immune response. However, it is 
possible that even the smaller amounts of tetanus Hc-based delivery 
agents are still non-functional in immunised humans. Even so, the utility 
of our current observation may still be beneicial for the hundreds of 
millions of non-immunised humans and possibly in veterinary medicine. 
We demonstrated here that duplication of the tetanus binding 
domain allows increased eficiency of delivery of an imaging reagent 
and a model enzyme, LC type A, into the spinal cord. This is likely not 
due to an acceleration of the transport of this chimeric protein but rather 
to the increase in binding to the neuronal membrane, since we have not 
observed any increase in accelerated intraneuronal traficking. It is more 
likely that there is an increase in internalisation rates of duplicated 
clostridial molecules from the plasma membrane since many receptor 
mechanisms exhibit enhancement in endocytosis in the case of dual 
binding (Vauquelin and Charlton, 2013). It will be important to address 
the enhancement mechanisms in future studies using advanced binding 
and imaging methods with high rate kinetic capabilities. Previously, it 
was proposed that the light chains and translocation domains of clos-
tridial neurotoxins, acting in conjunction with binding domains, dictate 
their local or distant destinations (Wang et al., 2012). Indeed, our study 
revealed a massive cleavage of SNAP-25 induced by Bitox/TT in the 
spinal cord neurons beyond the ventral horn but surprisingly with no 
visible effects on the motor behaviour of rats. Previously, a similar 
molecule called Tetbot was tested in rats at similar doses without any 
impediment of motor functions (Ferrari et al., 2013). It will be important 
to identify in future studies the nature of neurons which are targeted by 
the new chimeras and perform extensive studies of motor function, as it 
may be relevant to treatment of particular neurological disorders. 
Our data also show that duplication of botulinum binding domain 
derived from BoNT/D allows a high magniication of botulinum enzy-
matic activity delivered into human- and rat-derived neurons, raising 
the possibility that future botulinum therapeutics could be improved by 
simply adding an additional binding domain. We tested this possibility 
by remodelling the native BoNT/C with addition of the second HcC 
domain by direct fusion, rather than our trimeric assembly system. Our 
in vitro experiments revealed enhanced SNAP-25 cleaving ability of 
BoNT/CC versus the native toxin. We have not conducted in vivo studies 
with recombinant BoNT/CC due to regulatory restrictions but we 
envisage future translational studies in collaboration with industry. This 
is medically relevant since BoNT/C has been proposed as an alternative 
to the long-acting BoNT/A. Another beneit of duplication of botulinum 
binding domains is that the cleavage of SNAP-25 was accelerated in 
neuronal cultures which might translate into a therapeutic advantage 
but this possible acceleration needs to be also investigated in future 
physiological studies. 
Overall, we demonstrated that the duplication of the clostridial 
neuron-binding domains leads to increased delivery of enzymatic and 
imaging cargoes into neurons. With regards to future explorations, 
duplication of binding domains could be of homologous or heterologous 
nature, where binding domains can be coupled from different botulinum 
serotypes. It might be also possible to further increase intraneuronal 
Fig. 4. Recombinant duplication of the receptor-binding 
domain of BoNT/C (BoNT/CC) results in an enhancement 
of botulinum functions. a) Schematic (left panel) and 
Coomassie-stained SDS-PAGE gel (right panel) showing the 
difference between BoNT/C and the novel BoNT/CC. Pro-
teins were analysed in non-reducing conditions and thus 
exhibit full protein content. b) Immunoblot of SiMa neuro-
blastoma cells treated with either BoNT/C or BoNT/CC at 
indicated concentrations reveals a ive-fold enhancement of 
SNAP-25 cleavage by the duplicated molecule (BoNT/C EC50 
¼ 106 pM, BoNT/CC EC50 ¼ 20.4 pM) (n ¼ 3). c) Quantii-
cation of cell death in differentiated SiMa neuroblastoma cell 
culture treated with 2 nM of BoNT/C or BoNT/CC indicates 
three-fold increase in cytotoxic properties of the latter 
(BoNT/C ¼ 13.8%, BoNT/CC ¼ 53.2%) (n ¼ 3). d) Immu-
noblot of SiMa neuroblastoma cells treated with 3 nM either 
BoNT/C or BoNT/CC for indicated duration of time, with 
quantiication of cleaved SNAP-25 at 24 h shown in the bar 
chart (lower panel) (n ¼ 3).   
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delivery by adding more than two neuronal binding domains. This 
interesting possibility will need to be explored. Such enhanced botuli-
num therapeutics should achieve therapeutic effects with lower doses 
compared to the current doses of these bacterially-derived immunogenic 
molecules, especially where high doses are required, for example in the 
cases of severe migraine and cerebral palsy. Pertinently, a family of 
patents by Allergan highlighted possible therapeutic applications of 
multivalent botulinum neurotoxins (Steward et al., 2007). Finally, the 
enhanced botulinum therapeutics shall exhibit faster therapeutic effects 
beneitting many neurological patients under treatment with conven-
tional botulinum drugs. 
4. Methods 
4.1. Ethics statement 
All experimental procedures conformed to the European Commu-
nities Council Directive number 86/609/EEC. We have followed the 
rules of Three R’s to reduce the impact of research on animals. Animals 
were reared in a 12 h light/dark cycle, with food and water available ad 
libitum. Animal work was carried out under project licences in accor-
dance with the Animals (Scientiic Procedures) Act 1986 and its asso-
ciated guidelines. 
4.2. Protein production 
With the exception of BoNT/C-based proteins, all recombinant pro-
teins were made as glutathione-S-transferase (GST) C-terminal fusions 
cleavable by thrombin in the pGEX-KG expression vector and expressed 
in E. coli BL21-Gold-PLysS-DE3 (Agilent). Expressed proteins were pu-
riied by glutathione afinity chromatography and eluted from the 
glutathione beads using thrombin as described previously (Darios et al., 
2010). The linker 1 sequence is based on the sequence of rat VAMP2 
(2–84, UniProt P63045). Fusions of the linker 1 with the tetanus binding 
domain (HcT- 856–1315, Uniprot P04958) and the Botulinum binding 
domains type D (HcD- 865–1275, Uniprot P19321) were made by 
inserting the DNA sequence for VAMP2 (2–84, Uniprot P63045) into the 
XhoI site of the pGEX-KG vector and the DNA sequence for the relevant 
binding domain into the SacI site. The linker 2 was based on the SNARE 
helix of rat syntaxin 3 (195–253, Uniprot Q08849). Linker 2- HcT and 
linker 2-HcD, were each designed by inserting the DNA sequence for rat 
syntaxin 3 (195–253, Uniprot Q08849) into the XbaI site of the pGEX-KG 
vector and the DNA sequence of the relevant binding domain into the 
SacI site. The enzymatic portion of the botulinum type A1 neurotoxin 
consisting of its light chain and translocation domain fused to linker 3 
(based on the sequence of SNAP-25, aa 1–206) was prepared as previ-
ously described (Darios et al., 2010). For preparation of Cy3 molecules, 
the sequence for SNAP-25 was inserted into the BamHI site of the 
pGEX-KG plasmid. After protein expression, Cy3-NHS was conjugated to 
the free cysteines of SNAP-25 at 8-fold molar excess. Conjugated linker 
3-Cy3 was then puriied by gel iltration on Superdex-200 column. The 
single-Hc constructs were assembled using a synthetic syntaxin 3 pep-
tide as in (Darios et al., 2010). 
4.3. Formation of single- and double-ligand clostridial constructs 
Fusion proteins containing an eqimolar ratio of linker 1, linker 2 and 
linker 3 components were mixed in Buffer A (20 mM HEPES, 100 mM 
NaCl2 and 0.4% octyl glucoside) and were left at 20 �C for 1 h to allow 
formation of the SNARE helical bundle. Irreversible assembly of protein 
complexes was conirmed by sodium dodecyl sulphate–polyacrylamide 
gel electrophoresis (SDS–PAGE). The gels were run at 4 �C and proteins 
were visualised by Coomassie Blue staining, as described previously 
(Darios et al., 2010). 
4.4. Expression of BoNT/C and BoNT/CC 
pBoNT/Cs-thro was generated by inserting the full-length open 
reading frame for BoNT/C (Uniprot P18640) as an EcoRI-PstI fragment 
into pQE3 (Qiagen). It encodes in addition a Strep-tag, PGWSHPQFEK, 
following the C-terminal codon and an E. coli protease and thrombin 
sensitive peptide, SKTKSLVPRGS, replacing D442-N448 between LC and 
the heavy chain. pBoNT/CC was generated based on pBoNT/Cs by 
inserting a DNA segment encoding the lexible 40 aa linker, 
PGASGGGGASSAGGGSSAGSGSSGGGAAAGSGASGSASGS, between the 
C-terminal end, followed by a copy of the Hc-fragment encoding part of 
BoNT/C, (867–1291), and the Strep-tag coding segment. Recombinant 
full-length BoNT/C proteins were puriied from the E. coli strain 
M15pREP4 (Qiagen GmbH, Hilden, Germany), following 16 h of in-
duction at 21 �C. Proteins were puriied on Streptactin-Superlow beads 
(IBA GmbH), according to the manufacturer’s instructions and eluted in 
100 mM Tris–HCl, pH 8.0, 10 mM desthiobiotin. Both protein prepara-
tions were treated with thrombin-attached beads in the presence of 10 
mM CaCl2 for 2 h at 21 �C. Protein was collected in the low-through and 
stored at  80 �C. 
4.5. Cortical neuron cultures 
All cells and cell lines were maintained at 37 �C and 5% CO2. Cortical 
neurons were dissected from embryonic day 17.5 rat pups and washed in 
Hanks’ Balanced Salt Solution (HBSS), before treating with 70 μL of 2% 
Trypsin (Sigma) for 15 min at 37 �C, followed by addition in 5 μg of 
DNAse (Sigma). Cells were resuspended in 1 mL triturating solution (1% 
albumax (Gibco), 0.5 mg/mL Trypsin inhibitor (Sigma), 1 μg/mL DNAse 
in HBSS). Cells were triturated with 3 progressively smaller glass pi-
pettes before addition of cortical media up to 5 ml. 50,000 cells in 150 μL 
media were plated on 96 well plates coated with poly-D-lysine. Cells 
were maintained in Neurobasal medium (Gibco) supplemented with 1% 
B27 (Gibco), 1% Penicillin/streptomycin (Gibco), and 400 μM L-gluta-
mine (Gibco). Half of the medium was changed every 3–4 days and 
cultures were tested at least 1 week after plating and kept for a 
maximum of 4 weeks. 
4.6. Neuroblastoma cell cultures 
Media for the SiMa cell line contained 90% DMEM and 10% FBS. 
SiMa neuroblastoma cell differentiation medium contained 96% RPMI, 
10 mM HEPES pH 7.8, 1X non-essential amino acids (Gibco), 2% B27 
(Gibco) and 10 μM all trans-retinoic acid (Sigma). SiMa cells were 
differentiated by plating onto laminin-coated wells in a 96-well plate, at 
a density of 20,000 cells per well, in 150 μL of differentiation media 
(Rust et al., 2016). SiMa cells were used in experiments 72 h after in-
duction of differentiation. 
4.7. Motor neuron cultures 
Mouse spinal cord motor neurons were isolated from E13-14 em-
bryos and plated on poly-D-ornithine and laminin-coated 24 well plates, 
glass coverslips or 35-mm glass-bottom microwell dishes (MaTeK cor-
poration). Motor neurons were cultured for between ive and eight days 
in media containing Neurobasal medium supplemented with 2% B27, 
2% heat-inactivated horse serum, 1% GLUTAMAX, 25 μM 2-mercaptoe-
thanol, 10 ng/mL rat ciliary neurotrophic factor (CNTF; R&D Systems), 
100 pg/mL rat glial cell line-derived neurotrophic factor (GDNF; R&D 
Systems), 1 ng/mL brain derived neurotrophic factor (BDNF; R&D Sys-
tems) and 1% penicillin/streptomycin. 
4.8. Neuronal labelling 
Primary motor neurons were incubated with 10 nM 1xHcT-Cy3 or 
2xHcT-Cy3 for 30 min. Motor neurons on coverslips were ixed in 4% 
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PFA in phosphate buffer saline (PBS) for 15 min at 22 �C. Coverslips 
were then washed with PBS and permeabilised and blocked for 10 min in 
a solution of 5% BSA and 0.1% Triton X-100 in PBS. Primary antibodies 
were diluted in 5% bovine serum albumin (BSA) in PBS and incubated 
for 1 h at 22 �C. Coverslips were washed 3 times in PBS, then incubated 
with the appropriate luorescently conjugated secondary antibodies 
diluted in 5% BSA for 1 h at 22 �C. Finally, coverslips were washed 3 
times with PBS, once with water and then mounted using Mowiol-488. 
Coverslips were imaged with an invert Zeiss LSM 780 confocal micro-
scope using a 63X Plan-Apochromat oil immersion objective with an NA 
of 1.4. Immunoluorescence staining was quantiied using ImageJ. For 
live imaging, primary cortical or motor neurons were incubated with 10 
nM 1xHcT-Cy3 or 2xHcT-Cy3 for 30 min. Cultures were washed and 
fresh media was applied before imaging on an epiluorescence 
microscope. 
4.9. Measurement of axonal retrograde transport 
Primary motor neurons were incubated with 10 nM 1xHcT-Cy3 or 
2xHcT-Cy3 for 30 min. Cultures were washed and fresh motor neuron 
media was applied. Cells were then imaged using a Zeiss LSM 780 mi-
croscope equipped with a Zeiss X63, 1.40 NA DIC PlanApochromat oil- 
immersion objective whilst kept at 37 �C. Retrograde transport was 
quantiied using Motion Analysis software (Kinetic Imaging) as done 
previously (Gibbs et al., 2018). 
4.10. Investigation of Cy3-labelled luorescent constructs in mouse spinal 
cord 
2 months old Bl6/CJ male mice were anaesthetized using isolurane 
followed by intraplantar injections of luorescent HcT constructs into the 
right footpad (1 μg equivalent to 13 pmol for 1xHcT and 8 pmol 2xHcT) 
in a volume of 5 μl saline. Left foot served as negative control. 48 h after 
injection mice were perfused with 4% PFA, spinal cords isolated by 
laminectomy, post-ixed for 4 h in the ixative. Then samples were rinsed 
in PBS, and vibrotome slices of the L4-S2 spinal cord slices were cut to 
60 μm thickness. On average, 8 sections from each spinal cord sample 
had some degree of luorescent signal in the right hemisphere. Sections 
with the highest luorescent signal were selected from each mouse to 
count total number of luorescently labelled motor neuron cell bodies 
per section. 
4.11. Investigation of BiTox/T and BiTox/TT in mouse visual cortex 
2 months old mice were injected with 3 ng of Bitox/TT (13.3 fmol) or 
Bitox/T (17.1 fmol) into left visual cortex (coordinates: 3 mm lateral and 
in correspondence with lambda). Right and left visual cortices were 
dissected three days following injections. Proteins were extracted with 
lysis buffer (1% Triton X-100, 10% glycerol, 20 mM Tris-HCl, pH 7.5, 
150 mM NaCl, 10 mM EDTA, 0.1 mM Na3VO4, 1 μg/mL leupeptin, 1 μg/ 
mL aprotinin, and 1 mM PMSF), and the total concentration of the 
samples was assessed with a protein assay kit (Bio-Rad) using BSA as a 
standard. Immunoblotting was performed as described previously 
(Spalletti et al., 2017). Protein extracts were separated by electropho-
resis and then immunoblotted. Membranes were incubated with 1:5000 
dilution of either anti-cleaved SNAP-25 or anti-intact SNAP-25 primary 
antibody overnight at 4 �C. Anti-cleaved SNAP-25 was raised against a 
synthesized peptide of SNAP-25 190–197 (TRIDEANQ). For detection of 
native SNAP-25 we used rabbit polyclonal antibody against the native 
uncleaved SNAP-25 protein. Membranes were also probed with 
anti-alpha tubulin antibody (mouse monoclonal, 1:15,000 dilution; 
Sigma) as an internal standard for protein quantiication. Blots were 
then rinsed in PBS with 0.2% Tween 20, incubated in infrared labelled 
secondary antibodies (anti-mouse IRDye 680LT at 1:30,000 or 
anti-rabbit 800CW at 1:20,000; Li-Cor Biosciences), and rinsed in PBS. 
Membranes were scanned using an Odyssey IR scanner (Li-Cor 
Biosciences), and densitometry analysis was performed with Image 
Studio software version 3.1 (Li-Cor Biosciences). The band of interest 
was determined with respect to protein molecular weight standards. 
Antibody signal was calculated as integrated intensity of the region 
deined around the band of interest. Protein amount of cleaved SNAP-25 
and intact SNAP-25 was normalised relative to the alpha-tubulin 
immunosignal. 
4.12. Investigation of BiTox/T and BiTox/TT in rat spinal cord 
300 ng of single- (1.7 pmol) and double-liganded (1.3 pmol) botu-
linum constructs were injected into the left hind paw of rats. Group 1 (3 
rats) received BiTox/T whilst Group 2 (3 rats) received BiTox/TT. 6 days 
post injection, rats were sacriiced and perfused with 4% PFA. The spinal 
cords were removed and sectioned for immunohistochemistry. Spinal 
cord sections were incubated with anti-cleaved SNAP-25 antibody 
(1:10000 diluted in PBS) and left overnight on a rocker at 22 �C. The 
following day, the sections underwent three PBS washes before incu-
bation with biotinylated secondary antibodies (1:400 goat anti-rabbit, 
Vector Stain) for 90 min at 22 �C as part of a Tyramide Signal Ampli-
ication (TSA) protocol. After additional three washes, sections were 
incubated in ABC complex (1:125; Vector Stain, ABC elite kit, Vector 
Labs) for 30 min at 22 �C. After three washes with PBS, sections were 
incubated with biotinylated tyramide (1:75; TSA Stain Kit; PerkinElmer) 
for 7 min. The tissue sections were imaged using a Leica DM IRB epi-
luorescence microscope with MicroManager software. Image analysis 
and quantiication was performed using FIJI software for particle 
analysis. 
4.13. Western blotting analysis of botulinum activity in neuronal cell 
cultures 
Molecules containing botulinum type A or C protease were compared 
in differentiated neuroblastoma or cortical neurones for the cleavage of 
intraneuronal SNAP-25, which can be detected as a shift in the molec-
ular weight of SNAP-25 in SDS-PAGE gels. Immunoblotting was done 
using an in-house rabbit polyclonal SNAP-25 antibody which recognises 
both the intact and cleaved SNAP-25. Following treatment of cortical 
neurons or differentiated SiMa neuroblastoma cells with botulinum 
constructs for 65 h (unless otherwise stated) in 96 well plates, cell cul-
ture media was removed before addition of SDS-PAGE loading buffer 
(56 mM sodium dodecyl sulphate, 0.05 M Tris-HCl, pH 6.8, 1.6 mM 
EDTA, 6.25% glycerol, 0.0001% bromophenol blue, 10 mM MgCl2, 26 
U/mL benzonase). Plates were then shaken at 900 rpm for 10 min. 
Samples were boiled for 3 min at 95 �C and then run on 12% Novex 
SDS–PAGE gels (Invitrogen). For assessment of intraneuronal SNAP-25 
cleavage, gel running time was 2 h to increase separation between 
cleaved and intact SNAP-25. Following separation, proteins were 
transferred onto Immobilon-P membranes, and then incubated for 30 
min in blocking solution (5% milk, 0.1% Tween 20 in PBS). The rabbit 
SNAP-25 polyclonal antibody was added at 1:3000 dilution to the 
blocking solution at 4 �C overnight. Membranes were washed three 
times in 0.1% Tween 20 in PBS for 5 min and then incubated for 30 min 
in the blocking solution containing secondary peroxidase-conjugated 
donkey anti-rabbit antibodies (Amersham). Membranes were washed 
three times for 5 min in 0.1% Tween 20 in PBS. Immunoreactive protein 
bands were visualised using SuperSignal West Dura solution (Thermo 
Scientiic) on a BioRad imaging station and by exposure to X-Ray ilms 
(Fuji, UK). Protein bands were quantiied using the Quantity One soft-
ware (BioRad). EC50 values were calculated using the non-linear it 
equation in GraphPad Prism. 
4.14. Neuroblastoma cytotoxicity assay 
The cytotoxic effect of molecules containing the type C protease were 
compared in differentiated neuroblastoma using the Deep Blue Cell 
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Viability Kit (BioLegend). Following treatment of differentiated 
Nanoluc-VAMP2 expressing SiMa neuroblastoma with botulinum con-
structs for 65 h in 96 well plates, 15 μL of Deep Blue Cell Viability re-
agent was added to each well before incubation at 37 �C for 6 h. 
Fluorescence of the metabolised reagent was measured at Excitation 
560 nm and Emission 590 nm. Wells containing differentiation media 
alone were used as a negative control. Cell viability was normalised 
using the mean average of untreated cells as the 100% value. 
Statistical analysis 
All experiments were repeated at least three times and signiicance 
was determined using unpaired t-test. 
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